Search results | novartis


Partnering Agreements with Novartis

This report provides all the information you require to better understand Novartis and its partnering interests and activities over the past seven years.


More merger talks for Claris Lifesciences: Pfizer, Amneal, Novartis…

India-based CLARIS Lifesciences Ltd., which operates a generic sterile injectables business, has become the belle of the ball as multi-national companies such as Pfizer Inc., Amneal, Novartis AG and Indian companies such as Lupin and Cipla, are lining up to play the

Novartis eyes for more pharma deals in Israel

Novartis , the world’s biggest pharmaceutical (big pharma) company, recently increased its interest in Israel to sign pharma deals. For a long time, the company was active in marketing and clinical trials in Israel, and now it is involved in investment as well.


Novartis is a top pharmaceutical company based in Basel, Switzerland

Novartis and Merck & co are to exchange businesses

Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc’s over-the-counter products unit in a deal that could boost earnings at both companies.

Biotech rumor mills has it that Novartis Will Sell Its $14.1 Billion Stake

Biotech rumor mill has it that since Roche Share Discount Widens on Bet Novartis to Sell Stake for $14.1 billion.

Novartis is capable of spending $4-6 billion in m&a

Swiss drugmaker Novartis can spend $4-6 billion per year on m&a to strengthen its core pharma, eyecare and generics businesses or its three smaller units, its chief executive officer said in an interview on Sunday.

Novartis jumps on the bandwagon to sell it’s animal health sector

Novartis follows the lead of Pfizer and Merck & Co to sell it’s OTC and animal health sector. 

Roche and Novartis in merger and acquisition talks?

Merger and acquisition rumor mill :Roche Holding AG  founding families want the Swiss drugmaker to stay independent, Chief Executive Officer Severin Schwan said, squelching speculation that circulated since a board member at crosstown rival Novartis AG (NOVN) said last month a merger could make sense

Dealtalk: Novartis said to want out of Indian vaccines venture

In dealtalk, Novartis plans to exit an eight-year-old vaccines joint venture with India’s Panacea Biotec and intends to go it alone.

Dealtalk: Novartis Chairman Says $10 Billion Acquisition Within Reach

Novartis Chairman Joerg Reinhardt said a $10 billion purchase is possible as the drugmaker reviews its business, including units focused on animal health and vaccines, according to dealtalk.


Sorry, your search returned no results.


Novartis and Aduro Biotech in immuno-oncology pact

Aduro Biotech announced the establishment of a major collaboration with Novartis

Arrowhead acquires Novartis RNAi R&D portfolio

Arrowhead Research announced the acquisition of Novartis’ entire RNAi research and development portfolio and associated assets

Aspen Pharmacare acquires Mono-Embolex rights from Novartis

Aspen has entered into an agreement with Novartis in terms of which it will acquire the rights to Mono-Embolex

Array Biopharma acquires encorafenib rights from Novartis

Array BioPharma has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib

Novartis and Qualcomm Ventures punt $100 million on early stage companies

Novartis Pharmaceuticals announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies

Novartis and BioLineRx in drug discovery pact

BioLineRx has entered into a multi-year strategic collaboration agreement with Novartis Pharma designed to facilitate development and commercialization of Israeli-sourced drug candidates

Array Biopharma regains binimetinib from Novartis

Array BioPharma has reached a definitive agreement with Novartis to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials

CSL has acquired the Flu vaccine business from Novartis

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

Oxford BioMedica signs pharma licensing deal with Novartis

Oxford BioMedica has struck a pharma licensing deal worth $90 million with Novartis to manufacture goods that are needed for a highly experimental cancer research program.

Pfizer signs a pharma deal with Novartis for two COPD drugs

Pfizer has signed a pharma deal to promote two new drugs developed by Novartis.